Design Therapeutics, Inc. (DSGN)

US — Healthcare Sector
Peers: AURA  IMAB  GALT  ENGN  RCKT  LBRX  ALT  ANNX  KRRO  DMAC 

Automate Your Wheel Strategy on DSGN

With Tiblio's Option Bot, you can configure your own wheel strategy including DSGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol DSGN
  • Rev/Share 0.0103
  • Book/Share 3.7467
  • PB 2.3887
  • Debt/Equity 0.0052
  • CurrentRatio 25.1279
  • ROIC -0.3485

 

  • MktCap 509798533.0
  • FreeCF/Share -0.8931
  • PFCF -10.0396
  • PE -8.0156
  • Debt/Assets 0.0049
  • DivYield 0
  • ROE -0.2715

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 4
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Upgrade DSGN RBC Capital Mkts Sector Perform Outperform -- $13 Nov. 20, 2025

News

Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
DSGN
Published: August 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

CARLSBAD, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference on Thursday, September 4, 2025, at 10:55 a.m. ET in New York.

Read More
image for news Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy
DSGN
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral

Phase 2 biomarker trial in FECD patients anticipated to begin in the second half of 2025 Phase 2 biomarker trial in FECD patients anticipated to begin in the second half of 2025

Read More
image for news Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy

About Design Therapeutics, Inc. (DSGN)

  • IPO Date 2021-03-29
  • Website https://www.designtx.com
  • Industry Biotechnology
  • CEO Pratik Shah
  • Employees 56
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.